BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8627026)

  • 21. CD19-deficient mice exhibit poor responsiveness to oral immunization despite evidence of unaltered total IgA levels, germinal centers and IgA-isotype switching in Peyer's patches.
    Gärdby E; Lycke NY
    Eur J Immunol; 2000 Jul; 30(7):1861-71. PubMed ID: 10940875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice.
    Amuguni JH; Lee S; Kerstein KO; Brown DW; Belitsky BR; Herrmann JE; Keusch GT; Sonenshein AL; Tzipori S
    Vaccine; 2011 Jun; 29(29-30):4778-84. PubMed ID: 21565244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses.
    Tierney R; Beignon AS; Rappuoli R; Muller S; Sesardic D; Partidos CD
    J Infect Dis; 2003 Sep; 188(5):753-8. PubMed ID: 12934192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G).
    Morris CB; Cheng E; Thanawastien A; Cárdenas-Freytag L; Clements JD
    Vaccine; 2000 Mar; 18(18):1944-51. PubMed ID: 10699345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.
    Park EJ; Chang JH; Kim JS; Yum JS; Chung SI
    Exp Mol Med; 2000 Jun; 32(2):72-8. PubMed ID: 10926118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arginine enhances induction of T helper 1 and T helper 2 cytokine synthesis by Peyer's patch alpha beta T cells and antigen-specific mucosal immune response.
    Kobayashi T; Yamamoto M; Hiroi T; McGhee J; Takeshita Y; Kiyono H
    Biosci Biotechnol Biochem; 1998 Dec; 62(12):2334-40. PubMed ID: 9972259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.
    Lu X; Clements JD; Katz JM
    Vaccine; 2002 Jan; 20(7-8):1019-29. PubMed ID: 11803061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.
    Douce G; Giannelli V; Pizza M; Lewis D; Everest P; Rappuoli R; Dougan G
    Infect Immun; 1999 Sep; 67(9):4400-6. PubMed ID: 10456880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcutaneous immunization: T cell responses and boosting of existing immunity.
    Hammond SA; Walwender D; Alving CR; Glenn GM
    Vaccine; 2001 Mar; 19(17-19):2701-7. PubMed ID: 11257412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant.
    Jackson RJ; Fujihashi K; Xu-Amano J; Kiyono H; Elson CO; McGhee JR
    Infect Immun; 1993 Oct; 61(10):4272-9. PubMed ID: 8406816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity.
    Ryan EJ; McNeela E; Pizza M; Rappuoli R; O'Neill L; Mills KH
    J Immunol; 2000 Nov; 165(10):5750-9. PubMed ID: 11067933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
    Marinaro M; Boyaka PN; Jackson RJ; Finkelman FD; Kiyono H; Jirillo E; McGhee JR
    J Immunol; 1999 Jan; 162(1):114-21. PubMed ID: 9886376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses.
    Marinaro M; Boyaka PN; Finkelman FD; Kiyono H; Jackson RJ; Jirillo E; McGhee JR
    J Exp Med; 1997 Feb; 185(3):415-27. PubMed ID: 9053442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
    McCluskie MJ; Weeratna RD; Clements JD; Davis HL
    Vaccine; 2001 Jun; 19(27):3759-68. PubMed ID: 11395211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb.
    Nawar HF; Greene CJ; Lee CH; Mandell LM; Hajishengallis G; Connell TD
    Vaccine; 2011 Jan; 29(4):721-7. PubMed ID: 21095251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli.
    Yu J; Cassels F; Scharton-Kersten T; Hammond SA; Hartman A; Angov E; Corthésy B; Alving C; Glenn G
    Infect Immun; 2002 Mar; 70(3):1056-68. PubMed ID: 11854183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice.
    Bost KL; Holton RH; Cain TK; Clements JD
    Immunology; 1996 Apr; 87(4):633-41. PubMed ID: 8675220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids.
    Bowman CC; Clements JD
    Infect Immun; 2001 Mar; 69(3):1528-35. PubMed ID: 11179323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin.
    Xu-Amano J; Jackson RJ; Fujihashi K; Kiyono H; Staats HF; McGhee JR
    Vaccine; 1994 Aug; 12(10):903-11. PubMed ID: 7975832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.
    Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G
    Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.